February 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in March: TD Cowen 44th Annual Health Care Conference. Fireside chat on Monday, March 4, 2024 at 11:10 a.m. ET in Boston, MA. Leerink Global Biopharma Conference. Fireside chat on Monday, March 11, 2024 at 2:40 ...

February 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in March: TD Cowen 44th Annual Health Care Conference. Fireside chat on Monday, March 4, 2024 at 11:10 a.m. ET in Boston, MA. Leerink Global Biopharma Conference. Fireside chat on Monday, March 11, 2024 at 2:40 ...

February 22, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 29, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2023 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at a ...

Xenon Pharmaceuticals (XENE) - 联邦储备局计划降低利率，将使投资者更容易进入风险较高的经济和股市领域[1] - 生物技术股票通常根据其新技术或药物的试验和批准而波动，具有投机性[1] - Xenon Pharmaceuticals (XENE)开发了大量的神经疗法产品，目前主要在加拿大，市场对其表现持乐观态度[4] - Xenon Pharmaceuticals发布了XEN1101第三阶段项目，用于治疗重度抑郁症[5] - 分析师预计该公司未来12个月的每股收益将增长107.8%[6] Argenx (ARGX) - 前瞻市盈率为538.0倍，市场愿意为未来预期收益支付高昂的价格[8] - Argenx (ARGX)公司在自身网站上展示了其产品管道，该公司在自身产品的研发上表现出色[10] - ARGX-118项目目前处于第一阶段，可能很快引起市场关注，预计未来EPS增长约240.0%[13] IntraCellular Therapies (ITCI) - IntraCellular Therapies (ITCI)在处理神经疾病方面表现出色，分析师预计今年EPS增长225.8%[16]

Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics Lice ...

Key Points The healthcare sector is quickly heating up in all the fundamental ways professional traders seek. Within it, you can spot five stocks calling for new moves to the upside, backed by similar tailwinds. Analysts see the same factors at play and boldly project triple-digit EPS growth in all of them. 5 stocks we like better than Axsome Therapeutics While most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in t ...

Christoph Burgstedt Shares of argenx (NASDAQ:ARGX) have somewhat recovered from the negative reaction to the second late-stage clinical failure of Vyvgart in a row - phase 3 trial in immune thrombocytopenia ('ITP') and phase 3 trial in pemphigus vulgaris ('PV'). The recovery was probably driven by several factors - bargain hunters and the overall positive industry sentiment since early November and the company providing a bullish commercial and pipeline update ahead of and at the JPMorgan Healthcare Confere ...

argenx公司新药批准 - argenx公司宣布日本卫生劳动省批准VYVDURA用于治疗成人全身性重症肌无力症患者[2] - VYVDURA的批准基于来自第3期ADAPT-SC研究的积极结果，该研究证实了VYVDURA的疗效[3] - VYVDURA是一种皮下注射药物，结合了efgartigimod alfa和递归人透明质酸酶PH20，利用Halozyme的ENHANZE®药物递送技术[4]

医疗 - 生物医学和遗传学领域 - Argenx SE (ARGX) 是医疗 - 生物医学和遗传学领域的一个有趣选择[1] - 医疗 - 生物医学和遗传学领域目前处于一个良好的行业排名，有广泛的趋势正在推动该领域的证券[2] - Argenx 近期看起来也相当不错，过去一个月内，公司的盈利预期修订活动稳健，分析师对公司的前景变得更加乐观[3] - 公司目前持有 Zacks Rank 3 (Hold)，这也是一个有利的信号[4]

Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-2024 Reported positive data from Phase 2 ARDA study establishing proof-of-concept for empasiprubart in MMN Data from six Phase 2 proof-of-concept trials expected by end of 2024 Nominated four new pipeline candidates with IND filings expected by end of 2025 January 8, 2024, 7:00 AM CET Amsterdam, the Netherlands ...